Featuring perspectives from Prof John Bridgewater, including the following topics:

• Introduction: Biology and Epidemiology; Classification (0:00)
• Localized Biliary Tract Cancers (6:25)
• First-Line Treatment of Metastatic BTC (20:04)
• HER2-Positive Advanced BTC (24:22)
• Management of Mixed Hepatocellular Carcinoma/BTC Tumors (43:18)
• Advanced Cholangiocarcinoma with an FGFR2 Fusion (47:59)
• Other Important Issues in BTC (52:33)

CME information and select publications

Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics:

• Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00)
• Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39)
• Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22)
• Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25)
• Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30)
• Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25)
• Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48)
• Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37)
• Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05)
• Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26)
• Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37)
• Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59)
• Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22)

CME information and select publications

Featuring perspectives from Dr Arvind Dasari, Dr Christopher Lieu, Dr Van K Morris, Dr Jenny Seligmann and Prof Eric Van Cutsem, moderated by Dr Lieu, including the following topics:

• Introduction (0:00)
• Optimizing Biomarker Assessment for Patients with Colorectal Cancer (CRC) — Dr Dasari (2:18)
• Identification and Management of Metastatic CRC (mCRC) with a BRAF V600E Mutation — Dr Morris (26:37)
• Incorporation of Immune Checkpoint Inhibitors into the Management of Microsatellite Instability-High/Mismatch Repair-Deficient CRC — Dr Seligmann (49:46)
• Integration of Therapies Targeting HER2 into the Management of mCRC — Prof Van Cutsem (1:14:19)
• Biomarker-Based Decision-Making for Patients with mCRC and KRAS G12C Mutations — Dr Lieu (1:36:36)

CME information and select publications

Featuring an interview with Dr Surbhi Sidana, including the following topics:

• Long-term outcomes for patients with relapsed/refractory multiple myeloma (MM) (0:00)
• Clinical considerations in the selection of patients for chimeric antigen receptor (CAR) T-cell therapy (3:34)
• Practical challenges for patients receiving CAR T-cell therapy (8:34)
• Selection among available CAR T-cell therapies (12:18)
• Prevention, management and supportive care involved in the management of toxicities associated with CAR T-cell therapy (16:34)
• Secondary cancers associated with CAR T-cell therapy (21:25)
• Bridging therapy considerations for patients receiving CAR T-cell treatment (25:15)
• Utility of antibody-drug conjugates and bispecific antibodies for MM (27:49)
• Case: A man in his early 40s experiences rapid progression on induction therapy for MM (31:59)
• Case: A man in his early 50s with heavily pretreated MM receives multiple CAR T-cell therapies (41:47)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Surbhi Sidana, including the following topics:

• Key clinical data of FDA-approved chimeric antigen receptor (CAR) T-cell therapies (0:00)
• Real-world evidence evaluating utility of CAR T-cell therapies in the clinic (8:08)
• Impact of prior BCMA-targeted treatment on CAR T-cell therapy efficacy (12:55)
• Investigational CAR T-cell therapies in clinical development (15:08)
• Incidence and management of toxicities associated with CAR T-cell therapy (18:21)

CME information and select publications

Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics:

• Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00)
• Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53)
• Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14)
• Expanding the Spectrum of Targeted Therapy (38:52)
• Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13)
• Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35)
• Identification and Management of Adverse Events with T-DXd (1:20:27)
• Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02)
• Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58)

CME information and select publications

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics:

• Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry
  • Introduction (0:00)
  • Faculty Presentation (3:08)
  • IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43)
  • Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15)
  • Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34)
• Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn 
  • Faculty Presentation (31:18)
  • EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15)
  • Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29)
  • Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05)
• Current First-Line Therapy for Advanced HCC — Dr He
  • Faculty Presentation (1:00:39)
  • Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00)
  • Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22)
  • Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03)
• Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein 
  • Faculty Presentation (1:29:42)
  • Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59)
  • Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27)
  • Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20)

CME information and select publications

Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics:

• Introduction (0:00)
• First-Line Treatment of Metastatic Disease (2:34)
• Adjuvant and Neoadjuvant Therapy (22:31)
• EGFR Exon 20 Insertion Mutations (34:21)
• Antibody-Drug Conjugates (42:45)

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR Mutation-Positive NSCLC, Such as Nonmetastatic Disease, Exon 20 Insertion Mutations and Novel Agents — Helena Yu, MD

CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics:

• Therapy selection after CDK4/6 inhibitor failure: A review of current and investigational treatment for HR-positive, HER2-negative breast cancer
  • Astore S et al. A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: A review of current and investigational treatment for HR+/Her2- breast cancer. Crit Rev Oncol Hematol 2024;204:104535. Abstract (0:00)
• A preoperative window-of-opportunity study of the oral SERD imlunestrant for newly diagnosed ER-positive, HER2-negative localized breast cancer
  • Neven P et al. A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from the EMBER-2 Study. Clin Cancer Res 2024;30(23):5304-13. Abstract (3:30)
• An assessment of an exosome-based ESR1-monitoring RT-qPCR kit that detects acquired resistance variants in liquid biopsy samples
  • Statt S et al. An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples. ESMO 2024;Abstract 420P. (7:08)

CME information and select publications